ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment  

作　　者：Jeanny B Aragon-Ching 

机构地区：[1]GU Medical Oncology,Inova Schar Cancer Institute,Fairfax,VA 22031,USA

出　　处：《Asian Journal of Andrology》2023年第1期1-4,共4页亚洲男性学杂志（英文版）

摘　　要：ARASENS is an international phase III trial demonstrating the beneficial role of darolutamide,a novel antiandrogen,when added to docetaxel and androgen deprivation therapy(ADT),with improvement in overall survival in men with metastatic castration-sensitive or hormone-sensitive prostate cancer.Darolutamide is a nonsteroidal androgen receptor antagonist that has been previously shown to improve metastasis-free survival in nonmetastatic castration-resistant prostate cancer.ARASENS showed that the risk of death was 32.5%lower in those who received additional darolutamide compared to ADT and docetaxel alone.Darolutamide also improved other secondary endpoints including time to castrate-resistant disease,time to pain progression,time to first skeletal-related event,and subsequent initiation of therapy.ARASENS,therefore,shows that darolutamide,in addition to ADT and docetaxel,as a form of upfront systemic intensification of“triplet”therapy for patients deemed chemotherapy-fit,represents a new standard of care for men with metastatic hormone-sensitive or castrate-sensitive prostate cancer and is anticipated to further change the landscape of treatment for this population of patients.

关 键 词：ARAS TREATMENT chemotherapy metastasis ENS 

分 类 号：R737.25[医药卫生—肿瘤]